Clinical Trial Detail

NCT ID NCT02960594
Title hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Inovio Pharmaceuticals

colorectal cancer

stomach cancer

breast carcinoma

lung carcinoma

ovarian carcinoma

esophageal cancer

head and neck squamous cell carcinoma

hepatocellular carcinoma

pancreatic carcinoma


INO-1400 + INO-9012


Age Groups: adult senior

No variant requirements are available.